Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment.

Schanstra JP, Luong TT, Makridakis M, Van Linthout S, Lygirou V, Latosinska A, Alesutan I, Boehme B, Schelski N, Von Lewinski D, Mullen W, Nicklin S, Delles C, Feuillet G, Denis C, Lang F, Pieske B, Bascands JL, Mischak H, Saulnier-Blache JS, Voelkl J, Vlahou A, Klein J.

JCI Insight. 2019 May 16;4(10). pii: 125638. doi: 10.1172/jci.insight.125638. eCollection 2019 May 16.

2.

Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease.

Mokou M, Klein J, Makridakis M, Bitsika V, Bascands JL, Saulnier-Blache JS, Mullen W, Sacherer M, Zoidakis J, Pieske B, Mischak H, Roubelakis MG, Schanstra JP, Vlahou A.

EBioMedicine. 2019 Mar;41:91-104. doi: 10.1016/j.ebiom.2019.02.040. Epub 2019 Feb 28.

3.

The CKD plasma lipidome varies with disease severity and outcome.

Duranton F, Laget J, Gayrard N, Saulnier-Blache JS, Lundin U, Schanstra JP, Mischak H, Weinberger KM, Servel MF, Argilés A.

J Clin Lipidol. 2019 Jan - Feb;13(1):176-185.e8. doi: 10.1016/j.jacl.2018.07.010. Epub 2018 Aug 1.

PMID:
30177483
4.

Ldlr-/- and ApoE-/- mice better mimic the human metabolite signature of increased carotid intima media thickness compared to other animal models of cardiovascular disease.

Saulnier-Blache JS, Wilson R, Klavins K, Graham D, Alesutan I, Kastenmüller G, Wang-Sattler R, Adamski J, Roden M, Rathmann W, Seissler J, Meisinger C, Koenig W, Thiery J, Suhre K, Peters A, Kuro-O M, Lang F, Dallmann G, Delles C, Voelkl J, Waldenberger M, Bascands JL, Klein J, Schanstra JP.

Atherosclerosis. 2018 Sep;276:140-147. doi: 10.1016/j.atherosclerosis.2018.07.024. Epub 2018 Jul 21.

PMID:
30059845
5.

Lysophosphatidic Acid Protects Against Endotoxin-Induced Acute Kidney Injury.

Mirzoyan K, Denis C, Casemayou A, Gilet M, Marsal D, Goudounéche D, Faguer S, Bascands JL, Schanstra JP, Saulnier-Blache JS.

Inflammation. 2017 Oct;40(5):1707-1716. doi: 10.1007/s10753-017-0612-7.

PMID:
28667502
6.

Urinary lysophopholipids are increased in diabetic patients with nephropathy.

Saulnier-Blache JS, Feigerlova E, Halimi JM, Gourdy P, Roussel R, Guerci B, Dupuy A, Bertrand-Michel J, Bascands JL, Hadjadj S, Schanstra JP.

J Diabetes Complications. 2017 Jul;31(7):1103-1108. doi: 10.1016/j.jdiacomp.2017.04.024. Epub 2017 May 10.

PMID:
28506691
7.

Increased urine acylcarnitines in diabetic ApoE-/- mice: Hydroxytetradecadienoylcarnitine (C14:2-OH) reflects diabetic nephropathy in a context of hyperlipidemia.

Mirzoyan K, Klavins K, Koal T, Gillet M, Marsal D, Denis C, Klein J, Bascands JL, Schanstra JP, Saulnier-Blache JS.

Biochem Biophys Res Commun. 2017 May 20;487(1):109-115. doi: 10.1016/j.bbrc.2017.04.026. Epub 2017 Apr 7.

PMID:
28396151
8.

Increased urinary lysophosphatidic acid in mouse with subtotal nephrectomy: potential involvement in chronic kidney disease.

Mirzoyan K, Baïotto A, Dupuy A, Marsal D, Denis C, Vinel C, Sicard P, Bertrand-Michel J, Bascands JL, Schanstra JP, Klein J, Saulnier-Blache JS.

J Physiol Biochem. 2016 Dec;72(4):803-812. Epub 2016 Sep 17.

PMID:
27637780
9.

Shear Stress-Induced Alteration of Epithelial Organization in Human Renal Tubular Cells.

Maggiorani D, Dissard R, Belloy M, Saulnier-Blache JS, Casemayou A, Ducasse L, Grès S, Bellière J, Caubet C, Bascands JL, Schanstra JP, Buffin-Meyer B.

PLoS One. 2015 Jul 6;10(7):e0131416. doi: 10.1371/journal.pone.0131416. eCollection 2015.

10.

Autotaxin downregulates LPS-induced microglia activation and pro-inflammatory cytokines production.

Awada R, Saulnier-Blache JS, Grès S, Bourdon E, Rondeau P, Parimisetty A, Orihuela R, Harry GJ, d'Hellencourt CL.

J Cell Biochem. 2014 Dec;115(12):2123-32. doi: 10.1002/jcb.24889.

11.

Lysophosphatidic acid signaling in late cleavage and blastocyst stage bovine embryos.

Torres AC, Boruszewska D, Batista M, Kowalczyk-Zieba I, Diniz P, Sinderewicz E, Saulnier-Blache JS, Woclawek-Potocka I, Lopes-da-Costa L.

Mediators Inflamm. 2014;2014:678968. doi: 10.1155/2014/678968. Epub 2014 Apr 15.

12.

Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: in vivo and in vitro evidence.

Rancoule C, Viaud M, Gres S, Viguerie N, Decaunes P, Bouloumié A, Langin D, Bascands JL, Valet P, Saulnier-Blache JS.

Biochim Biophys Acta. 2014 Jan;1841(1):88-96. doi: 10.1016/j.bbalip.2013.10.003. Epub 2013 Oct 11.

PMID:
24120919
13.

Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis.

Rancoule C, Dusaulcy R, Tréguer K, Grès S, Attané C, Saulnier-Blache JS.

Biochimie. 2014 Jan;96:140-3. doi: 10.1016/j.biochi.2013.04.010. Epub 2013 Apr 29. Review.

PMID:
23639740
14.

Which bovine endometrial cells are the source of and target for lysophosphatidic acid?

Boruszewska D, Kowalczyk-Zieba I, Piotrowska-Tomala K, Saulnier-Blache JS, Acosta T, Skarzynski DJ, Woclawek-Potocka I.

Reprod Biol. 2013 Mar;13(1):100-3. doi: 10.1016/j.repbio.2013.01.166. Epub 2013 Jan 19.

PMID:
23522079
15.

Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice.

Rancoule C, Attané C, Grès S, Fournel A, Dusaulcy R, Bertrand C, Vinel C, Tréguer K, Prentki M, Valet P, Saulnier-Blache JS.

Diabetologia. 2013 Jun;56(6):1394-402. doi: 10.1007/s00125-013-2891-3. Epub 2013 Mar 19.

PMID:
23508306
16.

Influence of secreted factors from human adipose tissue on glucose utilization and proinflammatory reaction.

Tréguer K, Dusaulcy R, Grès S, Wanecq E, Valet P, Saulnier-Blache JS.

J Physiol Biochem. 2013 Sep;69(3):625-32. doi: 10.1007/s13105-013-0238-7. Epub 2013 Jan 27.

PMID:
23355066
17.

Cell autonomous lipin 1 function is essential for development and maintenance of white and brown adipose tissue.

Nadra K, Médard JJ, Mul JD, Han GS, Grès S, Pende M, Metzger D, Chambon P, Cuppen E, Saulnier-Blache JS, Carman GM, Desvergne B, Chrast R.

Mol Cell Biol. 2012 Dec;32(23):4794-810. doi: 10.1128/MCB.00512-12. Epub 2012 Oct 1.

18.

Plasticity-related gene-1 inhibits lysophosphatidic acid-induced vascular smooth muscle cell migration and proliferation and prevents neointima formation.

Gaaya A, Poirier O, Mougenot N, Hery T, Atassi F, Marchand A, Saulnier-Blache JS, Amour J, Vogt J, Lompré AM, Soubrier F, Nadaud S.

Am J Physiol Cell Physiol. 2012 Nov 15;303(10):C1104-14. doi: 10.1152/ajpcell.00051.2012. Epub 2012 Sep 26.

19.

Lysophosphatidic acid action in the bovine corpus luteum -an in vitro study.

Kowalczyk-Zieba I, Boruszewska D, Saulnier-Blache JS, Lopes Da Costa L, Jankowska K, Skarzynski DJ, Woclawek-Potocka I.

J Reprod Dev. 2012;58(6):661-71. Epub 2012 Aug 24.

20.

Depot-specific regulation of autotaxin with obesity in human adipose tissue.

Rancoule C, Dusaulcy R, Tréguer K, Grès S, Guigné C, Quilliot D, Valet P, Saulnier-Blache JS.

J Physiol Biochem. 2012 Dec;68(4):635-44. doi: 10.1007/s13105-012-0181-z. Epub 2012 May 27.

PMID:
22644624
21.

Autotaxin protects microglial cells against oxidative stress.

Awada R, Rondeau P, Grès S, Saulnier-Blache JS, Lefebvre d'Hellencourt C, Bourdon E.

Free Radic Biol Med. 2012 Jan 15;52(2):516-26. doi: 10.1016/j.freeradbiomed.2011.11.014. Epub 2011 Dec 8.

PMID:
22155714
22.

A hypomorphic mutation in Lpin1 induces progressively improving neuropathy and lipodystrophy in the rat.

Mul JD, Nadra K, Jagalur NB, Nijman IJ, Toonen PW, Médard JJ, Grès S, de Bruin A, Han GS, Brouwers JF, Carman GM, Saulnier-Blache JS, Meijer D, Chrast R, Cuppen E.

J Biol Chem. 2011 Jul 29;286(30):26781-93. doi: 10.1074/jbc.M110.197947. Epub 2011 Jun 1.

23.

Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium.

Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, Megens R, Heyll K, Chun J, Saulnier-Blache JS, Reinholz M, van Zandvoort M, Weber C, Schober A.

Cell Metab. 2011 May 4;13(5):592-600. doi: 10.1016/j.cmet.2011.02.016.

24.

Lysophosphatidic acid-1-receptor targeting agents for fibrosis.

Rancoule C, Pradère JP, Gonzalez J, Klein J, Valet P, Bascands JL, Schanstra JP, Saulnier-Blache JS.

Expert Opin Investig Drugs. 2011 May;20(5):657-67. doi: 10.1517/13543784.2011.566864. Epub 2011 Mar 24. Review.

PMID:
21434838
25.

Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid.

Dusaulcy R, Rancoule C, Grès S, Wanecq E, Colom A, Guigné C, van Meeteren LA, Moolenaar WH, Valet P, Saulnier-Blache JS.

J Lipid Res. 2011 Jun;52(6):1247-55. doi: 10.1194/jlr.M014985. Epub 2011 Mar 18.

26.

Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation.

Bot M, Bot I, Lopez-Vales R, van de Lest CH, Saulnier-Blache JS, Helms JB, David S, van Berkel TJ, Biessen EA.

Am J Pathol. 2010 Jun;176(6):3073-84. doi: 10.2353/ajpath.2010.090009. Epub 2010 Apr 29.

27.

Altered food consumption in mice lacking lysophosphatidic acid receptor-1.

Dusaulcy R, Daviaud D, Pradère JP, Grès S, Valet P, Saulnier-Blache JS.

J Physiol Biochem. 2009 Dec;65(4):345-50. doi: 10.1007/BF03185929.

PMID:
20358347
28.

Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, Grès S, Bendriss-Vermare N, Bollen M, Saez S, Aoki J, Saulnier-Blache JS, Clézardin P, Peyruchaud O.

PLoS One. 2010 Mar 17;5(3):e9741. doi: 10.1371/journal.pone.0009741.

29.

Seipin deficiency alters fatty acid Delta9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy.

Boutet E, El Mourabit H, Prot M, Nemani M, Khallouf E, Colard O, Maurice M, Durand-Schneider AM, Chrétien Y, Grès S, Wolf C, Saulnier-Blache JS, Capeau J, Magré J.

Biochimie. 2009 Jun;91(6):796-803. doi: 10.1016/j.biochi.2009.01.011. Epub 2009 Feb 6.

PMID:
19278620
30.

Lysophosphatic acid modulates prostaglandin secretion in the bovine uterus.

Woclawek-Potocka I, Komiyama J, Saulnier-Blache JS, Brzezicka E, Bah MM, Okuda K, Skarzynski DJ.

Reproduction. 2009 Jan;137(1):95-105. doi: 10.1530/REP-08-0209. Epub 2008 Oct 1.

PMID:
18829944
31.

S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.

Ferry G, Moulharat N, Pradère JP, Desos P, Try A, Genton A, Giganti A, Beucher-Gaudin M, Lonchampt M, Bertrand M, Saulnier-Blache JS, Tucker GC, Cordi A, Boutin JA.

J Pharmacol Exp Ther. 2008 Dec;327(3):809-19. doi: 10.1124/jpet.108.141911. Epub 2008 Aug 28.

PMID:
18755937
32.

Phosphatidic acid mediates demyelination in Lpin1 mutant mice.

Nadra K, de Preux Charles AS, Médard JJ, Hendriks WT, Han GS, Grès S, Carman GM, Saulnier-Blache JS, Verheijen MH, Chrast R.

Genes Dev. 2008 Jun 15;22(12):1647-61. doi: 10.1101/gad.1638008.

33.

Lysophosphatidic acid and renal fibrosis.

Pradère JP, Gonzalez J, Klein J, Valet P, Grès S, Salant D, Bascands JL, Saulnier-Blache JS, Schanstra JP.

Biochim Biophys Acta. 2008 Sep;1781(9):582-7. doi: 10.1016/j.bbalip.2008.04.001. Epub 2008 Apr 11. Review.

34.

Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.

van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR, Moolenaar WH.

Cancer Lett. 2008 Aug 8;266(2):203-8. doi: 10.1016/j.canlet.2008.02.052. Epub 2008 Apr 18.

35.

Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization.

Giganti A, Rodriguez M, Fould B, Moulharat N, Cogé F, Chomarat P, Galizzi JP, Valet P, Saulnier-Blache JS, Boutin JA, Ferry G.

J Biol Chem. 2008 Mar 21;283(12):7776-89. doi: 10.1074/jbc.M708705200. Epub 2008 Jan 6.

36.

LPA1 receptor activation promotes renal interstitial fibrosis.

Pradère JP, Klein J, Grès S, Guigné C, Neau E, Valet P, Calise D, Chun J, Bascands JL, Saulnier-Blache JS, Schanstra JP.

J Am Soc Nephrol. 2007 Dec;18(12):3110-8. Epub 2007 Nov 14.

37.

Adipogenesis-related increase of semicarbazide-sensitive amine oxidase and monoamine oxidase in human adipocytes.

Bour S, Daviaud D, Gres S, Lefort C, Prévot D, Zorzano A, Wabitsch M, Saulnier-Blache JS, Valet P, Carpéné C.

Biochimie. 2007 Aug;89(8):916-25. Epub 2007 Feb 24.

PMID:
17400359
38.

Secretion and lysophospholipase D activity of autotaxin by adipocytes are controlled by N-glycosylation and signal peptidase.

Pradère JP, Tarnus E, Grès S, Valet P, Saulnier-Blache JS.

Biochim Biophys Acta. 2007 Jan;1771(1):93-102. Epub 2006 Dec 6.

PMID:
17208043
39.

[Secretion and role of autotaxin and lysophosphatidic acid in adipose tissue].

Saulnier-Blache JS.

J Soc Biol. 2006;200(1):77-81. French.

PMID:
17144165
40.

Short- and long-term insulin-like effects of monoamine oxidases and semicarbazide-sensitive amine oxidase substrates in cultured adipocytes.

Carpéné C, Daviaud D, Boucher J, Bour S, Visentin V, Grès S, Duffaut C, Fontana E, Testar X, Saulnier-Blache JS, Valet P.

Metabolism. 2006 Oct;55(10):1397-405.

PMID:
16979412
41.

Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.

van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J.

Mol Cell Biol. 2006 Jul;26(13):5015-22.

42.

TNFalpha up-regulates apelin expression in human and mouse adipose tissue.

Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, Ayav A, Ziegler O, Carpene C, Saulnier-Blache JS, Valet P, Castan-Laurell I.

FASEB J. 2006 Jul;20(9):1528-30. Epub 2006 May 24.

PMID:
16723381
43.

Adipokine expression profile in adipocytes of different mouse models of obesity.

Boucher J, Castan-Laurell I, Daviaud D, Guigné C, Buléon M, Carpéné C, Saulnier-Blache JS, Valet P.

Horm Metab Res. 2005 Dec;37(12):761-7.

PMID:
16372231
44.

Effects of oral administration of benzylamine on glucose tolerance and lipid metabolism in rats.

Bour S, Visentin V, Prévot D, Daviaud D, Saulnier-Blache JS, Guigne C, Valet P, Carpéné C.

J Physiol Biochem. 2005 Jun;61(2):371-9.

PMID:
16180335
45.

Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity.

Mazereeuw-Hautier J, Gres S, Fanguin M, Cariven C, Fauvel J, Perret B, Chap H, Salles JP, Saulnier-Blache JS.

J Invest Dermatol. 2005 Sep;125(3):421-7.

46.

Tyramine, benzylamine, and to a lesser extent histamine, partially mimic the adipogenic effect of insulin in a human preadipocyte cell strain.

Bour S, Visentin V, Gres S, Saulnier-Blache JS, Wabitsch M, Carpéné C.

Inflamm Res. 2005 Apr;54 Suppl 1:S60-1. No abstract available.

PMID:
15928836
47.

[Lysophosphatidic acid: a new link between blood platelets and bone metastasis].

Peyruchaud O, Boucharaba A, Saulnier-Blache JS, Clézardin P.

Med Sci (Paris). 2005 Apr;21(4):353-5. French. No abstract available.

48.

Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2.

Simon MF, Daviaud D, Pradère JP, Grès S, Guigné C, Wabitsch M, Chun J, Valet P, Saulnier-Blache JS.

J Biol Chem. 2005 Apr 15;280(15):14656-62. Epub 2005 Feb 14.

49.

Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression.

Boucher J, Quilliot D, Pradères JP, Simon MF, Grès S, Guigné C, Prévot D, Ferry G, Boutin JA, Carpéné C, Valet P, Saulnier-Blache JS.

Diabetologia. 2005 Mar;48(3):569-77. Epub 2005 Feb 8.

50.

Apelin, a newly identified adipokine up-regulated by insulin and obesity.

Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpéné C, Audigier Y, Saulnier-Blache JS, Valet P.

Endocrinology. 2005 Apr;146(4):1764-71. Epub 2005 Jan 27.

PMID:
15677759

Supplemental Content

Loading ...
Support Center